Fusion Antibodies (LSE:FAB) Other Stockholders Equity: £0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Fusion Antibodies Other Stockholders Equity?

Fusion Antibodies LSE:FAB Other Stockholders Equity is £0.00 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Fusion Antibodies's Other Stockholders Equity for the quarter that ended in Sep. 2025 was £0.00 Mil.

Fusion Antibodies's quarterly Other Stockholders Equity increased from Sep. 2024 (£0.00 Mil) to Mar. 2025 (£0.00 Mil) but then declined from Mar. 2025 (£0.00 Mil) to Sep. 2025 (£0.00 Mil).

Fusion Antibodies's annual Other Stockholders Equity increased from Mar. 2023 (£-0.00 Mil) to Mar. 2024 (£0.00 Mil) and increased from Mar. 2024 (£0.00 Mil) to Mar. 2025 (£0.00 Mil).

Fusion Antibodies Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Fusion Antibodies's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies Other Stockholders Equity Chart

Fusion Antibodies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 0.00

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00

Fusion Antibodies Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of £0.00 Mil mean?
Fusion Antibodies (LSE:FAB) has a Other Stockholders Equity of £0.00 Mil as of Sep. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Fusion Antibodies and its competitors.
Is Fusion Antibodies' Other Stockholders Equity too high?
Fusion Antibodies' current Other Stockholders Equity is £0.00 Mil.
How does Fusion Antibodies' Other Stockholders Equity compare to VRTX and REGN?
Fusion Antibodies' Other Stockholders Equity of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current Other Stockholders Equity is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.10 — trading 143.8% above its estimated fair value. The current Other Stockholders Equity is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Other Stockholders Equity is £0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.